Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Pyrenacantha staudtii* extract is a botanical drug candidate derived from the ethanol extraction of the African medicinal plant *Pyrenacantha staudtii*. Traditionally used in African folklore for the treatment of various cancers, the extract has demonstrated significant in vitro anticancer activity against human epithelial MCF-7 breast cancer cells. Its primary mechanism of action involves the induction of anoikis, a form of apoptosis triggered by the loss of cell-matrix interactions. This is achieved through the downregulation of β1-integrin expression and the inhibition of focal adhesion kinase (FAK) phosphorylation at the Tyr397 site. The extract shows particular potential for the treatment of estrogen receptor-positive breast cancer, with IC50 values reported in the range of 23-38 μg/ml.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pyrenacantha staudtii extract.